Strides Pharma Science Limited
Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, and internationally. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, gels, powders, solids, ointments, and creams. It also develops branded generics products f… Read more
Strides Pharma Science Limited (STAR) - Net Assets
Latest net assets as of September 2025: ₹28.03 Billion INR
Based on the latest financial reports, Strides Pharma Science Limited (STAR) has net assets worth ₹28.03 Billion INR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹65.21 Billion) and total liabilities (₹37.18 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₹28.03 Billion |
| % of Total Assets | 42.98% |
| Annual Growth Rate | 13.17% |
| 5-Year Change | -8.09% |
| 10-Year Change | -11.0% |
| Growth Volatility | 46.85 |
Strides Pharma Science Limited - Net Assets Trend (2005–2025)
This chart illustrates how Strides Pharma Science Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Strides Pharma Science Limited (2005–2025)
The table below shows the annual net assets of Strides Pharma Science Limited from 2005 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | ₹25.86 Billion | +24.85% |
| 2024-03-31 | ₹20.72 Billion | -4.66% |
| 2023-03-31 | ₹21.73 Billion | -8.83% |
| 2022-03-31 | ₹23.83 Billion | -15.31% |
| 2021-03-31 | ₹28.14 Billion | +8.45% |
| 2020-03-31 | ₹25.95 Billion | -7.39% |
| 2019-03-31 | ₹28.02 Billion | +7.38% |
| 2018-03-31 | ₹26.09 Billion | -9.23% |
| 2017-03-31 | ₹28.74 Billion | -1.09% |
| 2016-03-31 | ₹29.06 Billion | +149.73% |
| 2015-03-31 | ₹11.64 Billion | +7.50% |
| 2014-03-31 | ₹10.82 Billion | -48.41% |
| 2013-03-31 | ₹20.98 Billion | +47.97% |
| 2012-03-31 | ₹14.18 Billion | -8.83% |
| 2011-03-31 | ₹15.55 Billion | +42.74% |
| 2010-03-31 | ₹10.90 Billion | +82.91% |
| 2009-03-31 | ₹5.96 Billion | +102.95% |
| 2008-03-31 | ₹2.94 Billion | -31.86% |
| 2007-03-31 | ₹4.31 Billion | +24.30% |
| 2006-03-31 | ₹3.47 Billion | +59.19% |
| 2005-03-31 | ₹2.18 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Strides Pharma Science Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 458919000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₹4.59 Billion | 17.98% |
| Common Stock | ₹921.63 Million | 3.61% |
| Other Comprehensive Income | ₹4.91 Billion | 19.25% |
| Other Components | ₹15.09 Billion | 59.15% |
| Total Equity | ₹25.52 Billion | 100.00% |
Strides Pharma Science Limited Competitors by Market Cap
The table below lists competitors of Strides Pharma Science Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ningxia Western Venture Industrial Co Ltd
SHE:000557
|
$573.05 Million |
|
Antin Infrastructure Partners
LSE:0AA5
|
$573.10 Million |
|
A-Zenith Home Furnishings Co Ltd
SHG:603389
|
$573.56 Million |
|
Ronglian Group Ltd
SHE:002642
|
$574.03 Million |
|
Nexpoint Residential Trust Inc
NYSE:NXRT
|
$572.92 Million |
|
Controladora Vuela Compañía de Aviación S.A.B. de C.V
MX:VOLARA
|
$572.91 Million |
|
SUN COUNTRY AIRL.HLD.-01
F:6X2
|
$572.79 Million |
|
NOS S.G.P.S. S.A
PINK:ZONNF
|
$572.74 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Strides Pharma Science Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 21,255,630,000 to 25,518,310,000, a change of 4,262,680,000 (20.1%).
- Net income of 35,934,550,000 contributed positively to equity growth.
- Dividend payments of 229,900,000 reduced retained earnings.
- New share issuances of 61,020,000 increased equity.
- Other comprehensive income decreased equity by 35,460,000.
- Other factors decreased equity by 31,467,530,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₹35.93 Billion | +140.82% |
| Dividends Paid | ₹229.90 Million | -0.9% |
| Share Issuances | ₹61.02 Million | +0.24% |
| Other Comprehensive Income | ₹-35.46 Million | -0.14% |
| Other Changes | ₹-31.47 Billion | -123.31% |
| Total Change | ₹- | 20.05% |
Book Value vs Market Value Analysis
This analysis compares Strides Pharma Science Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.16x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 37.52x to 3.16x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-03-31 | ₹23.33 | ₹875.45 | x |
| 2006-03-31 | ₹34.66 | ₹875.45 | x |
| 2007-03-31 | ₹42.22 | ₹875.45 | x |
| 2008-03-31 | ₹30.89 | ₹875.45 | x |
| 2009-03-31 | ₹46.39 | ₹875.45 | x |
| 2010-03-31 | ₹92.82 | ₹875.45 | x |
| 2011-03-31 | ₹143.26 | ₹875.45 | x |
| 2012-03-31 | ₹153.17 | ₹875.45 | x |
| 2013-03-31 | ₹226.30 | ₹875.45 | x |
| 2014-03-31 | ₹112.45 | ₹875.45 | x |
| 2015-03-31 | ₹127.87 | ₹875.45 | x |
| 2016-03-31 | ₹319.77 | ₹875.45 | x |
| 2017-03-31 | ₹302.71 | ₹875.45 | x |
| 2018-03-31 | ₹274.13 | ₹875.45 | x |
| 2019-03-31 | ₹295.70 | ₹875.45 | x |
| 2020-03-31 | ₹282.13 | ₹875.45 | x |
| 2021-03-31 | ₹309.52 | ₹875.45 | x |
| 2022-03-31 | ₹262.87 | ₹875.45 | x |
| 2023-03-31 | ₹245.57 | ₹875.45 | x |
| 2024-03-31 | ₹233.25 | ₹875.45 | x |
| 2025-03-31 | ₹277.31 | ₹875.45 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Strides Pharma Science Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 140.82%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 77.71%
- • Asset Turnover: 0.76x
- • Equity Multiplier: 2.37x
- Recent ROE (140.82%) is above the historical average (17.70%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | 21.06% | 9.81% | 0.82x | 2.62x | ₹231.08 Million |
| 2006 | 15.65% | 9.27% | 0.56x | 3.02x | ₹175.26 Million |
| 2007 | 10.64% | 5.41% | 0.61x | 3.25x | ₹24.23 Million |
| 2008 | -18.12% | -6.91% | 0.36x | 7.35x | ₹-777.80 Million |
| 2009 | 25.99% | 10.58% | 0.44x | 5.60x | ₹664.22 Million |
| 2010 | 13.20% | 8.41% | 0.40x | 3.89x | ₹265.76 Million |
| 2011 | 9.55% | 7.22% | 0.38x | 3.50x | ₹-58.31 Million |
| 2012 | 16.37% | 8.89% | 0.46x | 3.98x | ₹873.28 Million |
| 2013 | 41.76% | 38.39% | 0.46x | 2.37x | ₹6.44 Billion |
| 2014 | -18.54% | -17.40% | 0.51x | 2.08x | ₹-2.87 Billion |
| 2015 | 73.80% | 74.65% | 0.46x | 2.17x | ₹7.31 Billion |
| 2016 | 7.30% | 6.89% | 0.40x | 2.68x | ₹-773.83 Million |
| 2017 | 14.75% | 11.91% | 0.41x | 2.99x | ₹1.29 Billion |
| 2018 | 26.91% | 23.62% | 0.43x | 2.67x | ₹4.15 Billion |
| 2019 | 12.26% | 11.03% | 0.37x | 3.02x | ₹597.48 Million |
| 2020 | 1.44% | 1.37% | 0.43x | 2.43x | ₹-2.16 Billion |
| 2021 | 9.67% | 8.18% | 0.47x | 2.53x | ₹-92.24 Million |
| 2022 | -19.51% | -14.99% | 0.44x | 2.96x | ₹-6.96 Billion |
| 2023 | -10.00% | -6.03% | 0.55x | 3.00x | ₹-4.42 Billion |
| 2024 | -3.32% | -1.84% | 0.66x | 2.75x | ₹-2.83 Billion |
| 2025 | 140.82% | 77.71% | 0.76x | 2.37x | ₹33.38 Billion |
Industry Comparison
This section compares Strides Pharma Science Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $12,445,167,922
- Average return on equity (ROE) among peers: 14.66%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Strides Pharma Science Limited (STAR) | ₹28.03 Billion | 21.06% | 1.33x | $572.99 Million |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $802.45 Million | 7.70% | 1.12x | $11.20 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $1.12 Billion | 12.32% | 2.74x | $149.72 Million |
| Abbott India Limited (ABBOTINDIA) | $42.33 Billion | 33.41% | 0.40x | $1.59 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $15.68 Billion | 32.33% | 0.16x | $1.46 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $7.20 Billion | -0.56% | 3.88x | $123.83 Million |
| Albert David Limited (ALBERTDAVD) | $2.44 Billion | 9.06% | 0.40x | $15.85 Million |
| Alivus Life Sciences Limited (ALIVUS) | $28.17 Billion | 17.24% | 0.21x | $333.13 Million |
| Alkem Laboratories Limited (ALKEM) | $23.74 Billion | 20.90% | 0.71x | $2.41 Billion |
| Alpa Laboratories Limited (ALPA) | $56.73 Million | 0.53% | 2.47x | $5.55 Million |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $2.91 Billion | 13.70% | 0.25x | $77.60 Million |